Impact of body mass index on outcome after percutaneous coronary intervention (the obesity paradox)

This publication has 9 references indexed in Scilit:

• The impact of body mass index onshort- and long-term outcomes inpatients undergoing coronary revascularization
  Journal of the American College of Cardiology, 2002
• Body-Mass Index and Mortality in a Prospective Cohort of U.S. Adults
  New England Journal of Medicine, 1999
• Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade
  The Lancet, 1998
• Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary Revascularization
  New England Journal of Medicine, 1997
• Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II
  The Lancet, 1997
• Low-Normal or Excessive Body Mass Index: Newly Identified and Powerful Risk Factors for Death and Other Complications With Percutaneous Coronary Intervention
  The American Journal of Cardiology, 1996
• Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary Angioplasty
  New England Journal of Medicine, 1994
• Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase
  Journal of the American College of Cardiology, 1988
• Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy
  The American Journal of Medicine, 1987